MyFinsight
Home
Blog
About
Available-for-sale marketable
securities
$81,636K
(-54.17%↓ Y/Y)
Cash and cash
equivalents
$39,028K
(45.36%↑ Y/Y)
Prepaid expenses and
other current assets
$3,804K
(-34.58%↓ Y/Y)
Total current assets
$124,468K
(-41.20%↓ Y/Y)
Operating lease
right-of-use assets
$31,772K
(-14.78%↓ Y/Y)
Property and equipment,
net
$9,896K
(-34.52%↓ Y/Y)
Restricted cash
$4,393K
(-16.29%↓ Y/Y)
Long-term investments
$2,154K
(0.00%↑ Y/Y)
Other assets
$1,018K
(26.46%↑ Y/Y)
Total assets
$173,701K
(-36.21%↓ Y/Y)
Total liabilities and
stockholders' equity
$173,701K
(-36.21%↓ Y/Y)
Total stockholders'
equity
$112,567K
(-42.52%↓ Y/Y)
Total liabilities
$61,134K
(-20.04%↓ Y/Y)
Accumulated deficit
-$361,411K
(-34.88%↓ Y/Y)
Accumulated other
comprehensive income (loss)
-$122K
(-132.80%↓ Y/Y)
Additional
paid-in-capital
$474,096K
(2.31%↑ Y/Y)
Non-current portion of
operating lease...
$31,485K
(-16.00%↓ Y/Y)
Total current
liabilities
$27,632K
(-16.93%↓ Y/Y)
Other non-current
liabilities
$2,017K
(-6.32%↓ Y/Y)
Common stock 0.0001 par
value 500,000,000...
$4K
(0.00%↑ Y/Y)
Deferred revenue
$11,198K
(-40.88%↓ Y/Y)
Accrued expenses and
other current...
$7,596K
(28.22%↑ Y/Y)
Current portion of
operating lease...
$6,235K
(13.20%↑ Y/Y)
Accounts payable
$2,603K
(-9.96%↓ Y/Y)
Back
Back
Balance Sheet
Metagenomi Therapeutics, Inc. (MGX)
Metagenomi Therapeutics, Inc. (MGX)
source: myfinsight.com